ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, David Cibula, Nicole Concin et al.|Annals of Oncology|2019Cited by 1.2k
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Xavier Matías‐Guiu et al.|Annals of Oncology|2024Cited by 277
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cellsMara Artibani, Ahmed A. Ahmed, Kenta Masuda et al.|JCI Insight|2021Cited by 42
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancerEleni Frangou, Sarah P. Blagden, Gianfilippo Bertelli et al.|Gynecologic Oncology|2021Cited by 22
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationJoaquı́n Mateo, L Rhoda Molife, Michael Friedländer et al.|Unknown|2013Cited by 19